Efficacy of sertraline in the treatment of depression in patients with Parkinson's disease.
Objective: We investigated the efficacy and safety of sertraline in the treatment of depression in patients with Parkinson's disease (PD) without motor oscillations. Sertraline has less potential for pharmacokinetic drug interactions than other antidepressants and this feature ensures an tolerabilit...
| Publicado en: | Turkiye Klinikleri Journal of Medical Sciences Vol. 30; no. 6; pp. 1852 - 1858 |
|---|---|
| Autores principales: | , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Turkiye Klinikleri
Dec2010
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104812771&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 104812771 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 13000292 1VOP jtl: Turkiye Klinikleri Journal of Medical Sciences issn: 13000292 maglogo: N pubinfo: dt: Dec2010 vid: 30 iid: 6 pid: 67298 pub: Turkiye Klinikleri artinfo: ui: 104812771 2010937911 10.5336/medsci.2009-14160 104812771 ppf: 1852 ppct: 6 formats: fmt: @attributes: type: P tig: atl: Efficacy of sertraline in the treatment of depression in patients with Parkinson's disease. aug: au: Torun, Fuat Bayülkem, Kemal Torun, Sebahat Dilek affil: Department of Psychiatry, Ümraniye Training and Resarch Hospital sug: subj: Depression Drug Therapy Parkinson Disease Complications Sertraline Hydrochloride Therapeutic Use Aged Data Analysis Software Descriptive Statistics Female Hamilton Rating Scale for Depression Human Male Middle Age Prospective Studies Psychological Tests Scales Wilcoxon Rank Sum Test Aged: 65+ years Middle Aged: 45-64 years Female Male ab: Objective: We investigated the efficacy and safety of sertraline in the treatment of depression in patients with Parkinson's disease (PD) without motor oscillations. Sertraline has less potential for pharmacokinetic drug interactions than other antidepressants and this feature ensures an tolerability profile especially in the elderly. Material and Methods: Sixteen patients with PD who were diagnosed with major depression according to DSM-IV criteria were included in this open-label trial for 8th weeks. Anti-parkinsonian medications have not been modified throughout the study period. Initial sertraline dose was 25 mg for the first week and then incrased to 50 mg given every morning. For assessment of depression, Beck Depression Inventory (BDI) and Hamilton Depression Rating Scale (HAM-D) were used and Unified Parkinson's Disease Rating Scale (UPDRS) and Hoehn-Yahr Scale were used for parkinsonism. Results: BDI and HAM-D scores decreased significantly (p= 0.000) and clinical global assessment of efficacy revealed 'good' or 'excellent' responses in all patients. Mean parkinsonian disability, as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS) and Hoehn and Yahr Stage scales, remained unchanged throughout the study in the group as a whole. Conclusion: Although these preliminary results need to be confirmed in large placebo-controlled trials, the results of the present study suggest that sertraline does not worsen motor performance and may be useful in the treatment of depression in PD. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|